PTC Therapeutics Inc

PTCT

74.680USD

+2.320+3.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

PTC Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

39 / 159

Overall Ranking

111 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PTC Therapeutics Inc Highlights

StrengthsRisks

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 15.45% year-on-year.

Overvalued

The company’s latest PE is 7.82, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 86.54M shares, decreasing 3.77% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 269.01K shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

87.267

Target Price

+20.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of PTC Therapeutics Inc is 7.51, ranking 109 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 211.01M, representing a year-over-year increase of 7.23%, while its net profit experienced a year-over-year increase of 114.90%.

Score

Industry at a Glance

Previous score

7.51

Change

0



Financials

7.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

3.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.49

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of PTC Therapeutics Inc is 8.42, ranking 19 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 7.82, which is 15.49% below the recent high of 9.04 and 254.57% above the recent low of -12.09.

Score

Industry at a Glance

Previous score

8.42

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of PTC Therapeutics Inc is 7.75, ranking 96 out of 159 in the Pharmaceuticals industry. The average price target is 80.00, with a high of 118.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

7.75

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of PTC Therapeutics Inc is 7.25, ranking 70 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 79.97 and the support level at 69.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of PTC Therapeutics Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 107.79%, representing a quarter-over-quarter increase of 8.29%. The largest institutional shareholder is The Vanguard, holding a total of 8.79M shares, representing 10.94% of shares outstanding, with 0.94% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.27M

-6.30%

RTW Investments L.P.

7.75M

--

BlackRock Institutional Trust Company, N.A.

5.69M

-1.77%

Wellington Management Company, LLP

4.92M

+4.78%

Janus Henderson Investors

3.77M

+18.85%

Armistice Capital LLC

3.28M

-30.79%

TD Securities, Inc.

3.25M

+32.73%

State Street Investment Management (US)

3.13M

+4.62%

D. E. Shaw & Co., L.P.

2.17M

-10.79%

Geode Capital Management, L.L.C.

1.95M

+0.84%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PTC Therapeutics Inc is 6.71, ranking 48 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. PTC Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

PTC Therapeutics Inc

PTCT

7.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment